



Oncology Drugs Division

No. KMSCL/DRG/ED/998/2019

www.kmscl.kerala.gov.in

Date : 09.06.2021

CIRCULAR

Sub:- KMSCL- Procurement of Anti Cancer Drugs to Cancer Care centres for the year 2020-21 - Exemption of NABL test reports - Circular Issued- reg

Ref:- 1. Tender No KMSCL/OD/AC/RC/2020/001 dated 20.02.2020


2. Tender No KMSCL/OD/AC/RT/2020/008 dated 16.09.2020

- 1) The e-tender process for the Procurement of Anti Cancer Drugs to RCC, MCC, CCRC and Institutions under DME & DHS and Non Anti Cancer Drugs for Cancer Care centres for the year 2020-21 invited vide references 1st & 2nd cited were finalized.
- 2) As per the urgent requirement intimated from the Cancer Care centres purchase orders for Anti Cancer drugs for the additional quantity requested by the centres were placed with the suppliers on 01.06.2021 & 07.06.2021.
- 3) The Corporation have received several representations from the suppliers that due to wide spread of COVID-19, there is an acute shortage of major Active Pharmaceutical Ingredients (API) and other Raw Materials in India and there is a delay in getting NABL test reports.
- 4) In light of the above, KMSCL is pleased to issue the following relaxations in the supply conditions in order to ensure the availability of Drugs for Cancer care Centres.

I.	EXEMPTION OF NABL TEST REPORT
a.	The supplies received against the Purchase Orders placed during the month of June 2021 (Anti Cancer) will be accepted in district drug warehouses considering the In house Test reports without insisting of test reports from NABL accredited testing laboratories.

I.	EXEMPTION OF NABL TEST REPORT
b.	The supplier shall forward IN-HOUSE test report to the Quality Control Division of the Corporation through e-mail qcapproval@gmail.com , before shipment.
c.	However, the suppliers are directed to submit the NABL test reports subsequently at the Head office of the Corporation and the final payments against these supplies will be settled upon receipt of test reports from NABL accredited testing laboratories.

All the other terms and conditions in the tender and the Purchase order remain unchanged.


 9.6.21
 MANAGING DIRECTOR &
 TENDER INVITING AUTHORITY